EIF4E2 (Gene)

Organism:

Homo sapiens

Synonyms:4E-LP, 4EHP, EIF4E2, EIF4EL3, ENTREZ:9470, HGNC:3293, IF4e, MIM:605895, NM_001276336, NM_001276337, NM_001282958, NM_001330201, NM_001330202, NM_001330203, NM_004846, NP_001263265, NP_001263266, NP_001269887, NP_001317130, NP_001317131, NP_001317132, NP_004837, eukaryotic translation initiation factor 4E family member 2, h4EHP

Id:ENSG00000135930

Entrez:9470

Ensembl:ENSG00000135930

Description:eukaryotic translation initiation factor 4E family member 2

Enables ubiquitin protein ligase binding activity. Involved in positive regulation of miRNA mediated inhibition of translation. Acts upstream of or within negative regulation of translation. Located in P-body. Part of mRNA cap binding activity complex. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View EIF4E2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with EIF4E2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using EIF4E2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for EIF4E2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with EIF4E2.

Results found

Linked to

	Label	Description
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 8 V 7 SAHA HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE164874 5 V 10 PREDNISOLONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 8 V 7 SAHA HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE164874 5 V 10 PREDNISOLONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE199107 tryptophan 0 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.